Treating PCOS With Digital CBT vs. Metformin

Sponsor
Shanghai 10th People's Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05386706
Collaborator
(none)
80
2
24

Study Details

Study Description

Brief Summary

With the change in environment and lifestyle, and the improvement of people's understanding of PCOS, the incidence of PCOS is increasing worldwide. According to statistics, the prevalence of PCOS in premenopausal women is as high as 5-20%. Lifestyle interventions are the main treatment option for patients with PCOS. In addition, research has shown that digital therapy can effectively improve behavior change in diet, exercise, and medication adherence, predict disease progression, reduce the frequency of disease-related symptoms, and promote effective disease management. Besides, cognitive behavioral therapy plays an important role in managing and maintaining a healthy lifestyle. This study aimed to investigate the efficacy of digital cognitive behavioral therapy versus traditional metformin monotherapy in overweight/obese patients with PCOS.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Based on the cognitive-behavioral therapy (CBT) model, this study developed a mini-program that combined diet, exercise, sleep, and mood interventions for PCOS women.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Treating Polycystic Ovarian Syndrome (PCOS) With Digital Cognitive Behavior Therapy (CBT) vs. Metformin
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Digital Cognitive Behavioural Therapy

A mini program-based cognitive behavioral therapy.

Behavioral: Digital Cognitive Behavioral Therapy
Based on the cognitive-behavioral therapy (CBT) model, this study developed a mini-program that combined diet, exercise, sleep, and mood interventions for PCOS women.
Other Names:
  • Digital CBT
  • Active Comparator: Metformin

    Traditional metformin monotherapy.

    Drug: Metformin
    Traditional metformin monotherapy.
    Other Names:
  • Metformin treatment
  • Outcome Measures

    Primary Outcome Measures

    1. Homeostasis model assessment of insulin resistance [3 months]

      insulin resistance index

    Secondary Outcome Measures

    1. Anthropometry [3 months]

      body mass index (kg/m2)

    2. menstrual frequency [3 months]

      number of menstruation in a year

    3. fasting glucose [3 months]

      fasting glucose(mmol/L)

    4. fasting insulin [3 months]

      fasting insulin(mmol/L)

    5. Total cholesterol [3 months]

      Total cholesterol (mmol/L)

    6. Triglycerides [3 months]

      Triglycerides (mmol/L)

    7. HDL-c [3 months]

      HDL-c (mmol/L)

    8. LDL-c [3 months]

      LDL-c (mmol/L)

    9. total testosterone [3 months]

      total testosterone (nmol/L)

    10. free testosterone [3 months]

      free testosterone (nmol/L)

    11. Sex hormone-binding globulin [3 months]

      Sex hormone-binding globulin (nmol/L)

    12. Androstenedione [3 months]

      Androstenedione (ng/ml)

    13. Dehydroepiandrosterone [3 months]

      Dehydroepiandrosterone (ug/dl)

    14. Food Frequency Questionnaire (FFQ) [3 months]

      Assess diet situation in women with PCOS.

    15. International Physical Activity Questionnaire (IPAQ) [3 months]

      Assess physical activity situation in women with PCOS.

    16. Pittsburgh Sleep Quality Index (PSQI) [3 months]

      Assess sleep situation in women with PCOS.

    17. Hospital Anxiety and Depression Scale (HADS) [3 months]

      To evaluate anxiety and depression in PCOS women.

    18. Three-Factor Eating Questionnaire (TFEQ-R21) [3 months]

      Assess eating behavior in women with PCOS.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Female aged 18- 45; Meet Rotterdam criteria; overweight/obesity, BMI≥23kg/m2

    Exclusion Criteria:

    Women who are pregnant or have a pregnancy plan within six months; Congenital adrenocortical hyperplasia; Hyperprolactinemia; Hyperthyroidism or hypothyroidism; Abnormal liver function (≥ 3 times the upper limit of the normal range); Abnormal renal function (GFR<60ml/min/1.73m2); Adrenal or ovarian tumors secreting androgens; Used contraceptives, metformin, pioglitazone, and contraceptives in the last 3 months.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Shanghai 10th People's Hospital

    Investigators

    • Study Chair: Shen Qu, Doctor, Shanghai 10th People's Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zhang Manna, Director, Principal Investigator, Clinical Professor, Shanghai 10th People's Hospital
    ClinicalTrials.gov Identifier:
    NCT05386706
    Other Study ID Numbers:
    • dCBT PCOS
    First Posted:
    May 23, 2022
    Last Update Posted:
    May 23, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 23, 2022